Immunocore Appoints New CMO and CFO

TL;DR

Immunocore names new CMO & CFO, effective Aug 28. Big leadership changes!

AI Summary

Immunocore Holdings plc announced on August 28, 2024, the appointment of Dr. Joern Hoch as Chief Medical Officer and Ms. Sarah O'Connor as Chief Financial Officer. The company also reported on compensatory arrangements for these key officers, effective August 28, 2024. This filing also includes information regarding the departure of certain officers and the election of directors.

Why It Matters

The appointment of a new Chief Medical Officer and Chief Financial Officer can signal strategic shifts in the company's direction and financial management, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in key executive positions like CMO and CFO can introduce uncertainty regarding future strategy and financial stability.

Key Players & Entities

• Immunocore Holdings plc (company) — Registrant
• Dr. Joern Hoch (person) — Appointed Chief Medical Officer
• Ms. Sarah O'Connor (person) — Appointed Chief Financial Officer
• August 28, 2024 (date) — Effective date of appointments

FAQ

Filing Documents

• ef20035097_8k.htm (8-K) — 36KB
• ef20035097_ex99-1.htm (EX-99.1) — 16KB
• graphic1.jpg (GRAPHIC) — 9KB
• logo1.jpg (GRAPHIC) — 6KB
• 0001140361-24-039083.txt ( ) — 214KB
• imcr-20240828.xsd (EX-101.SCH) — 4KB
• imcr-20240828_lab.xml (EX-101.LAB) — 21KB
• imcr-20240828_pre.xml (EX-101.PRE) — 16KB
• ef20035097_8k_htm.xml (XML) — 4KB

02

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Financial Officer On August 28, 2024, Mr. Brian Di Donato notified Immunocore Holdings plc (the "Company") of his decision to resign as Executive Vice President, Chief Financial Officer and Head of Strategy and principal financial officer of the Company, effective December 31, 2024, to pursue another opportunity. Mr. Di Donato's resignation was not because of any disagreement with the Company on any matter relating to the Company's financial statements, internal controls, operations, policies or practices, including accounting principles and practices. The Company has begun conducting a formal search for his replacement.

01

Item 7.01. Regulation FD Disclosure A copy of the press release announcing the departure of Mr. Di Donato is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release dated August 29, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOCORE HOLDINGS PLC Dated: August 29, 2024 By: /s/ Bahija Jallal, Ph.D. Name: Bahija Jallal, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR